...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Promissory Note

Since the last Exempt Distribution, on January 27th, ZCC reports a Promissory Note for $447,125.00 CAD. With this they also issued 100,000 common share purchase warrants exercisable at $1.92 until January 27th, 2026.

Share
New Message
Please login to post a reply